Skip to content Skip to footer
Omnichannel pharma in Italy: the paradox of the 64% F2F

Veeva Pulse 2025: 78% of global HCP interactions remain face-to-face. In Italy 64% of impactable sales come from direct contact, the highest share in EU5. Across Health measures that European HCPs want remote engagement at 60% and receive it at 40%. What it really means to orchestrate in a market that remains F2F-dominant.

Close
Close